TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06405061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab: 1200 mg, IV, q3w
Study: NCT05733624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCAI-001 0.01% eyedrop
Description: BID for 12weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCAI-001 0.02% eyedrop
Description: BID for 12weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis 0.05% eyedrop
Description: BID for 12weeks
Study: NCT05320523

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM.
Description: Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM, at the same trajectory.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM.
Description: Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM, at the same trajectory.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GPi stimulation
Description: Bilateral high-frequency neurostimulation of the GPi using a Vercise neurostimulation system

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GPi stimulation
Description: Bilateral high-frequency neurostimulation of the GPi using a Vercise neurostimulation system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NBM stimulation
Description: Bilateral low-frequency neurostimulation of the NBM using a Vercise neurostimulation system

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Ineffective neurostimulation by setting 0mA output at the Vercise neurostimulation system
Study: NCT05242848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: The intervention is a supervised group-based exercise intervention for 16 weeks, including two outdoor sessions per week. The workout consists of two parts, endurance and a strength training segment. Every workout follows the same structure and lasts approximately 45 minutes. The exercise starts with roughly 15 minutes of endurance warm-up. After the warm-up follows the interval with eight repetitions of 30 seconds uphill, and the participants can freely choose between walking or running. The desired intensity of the intervals is \>13 on Borg-score 20. The session will end with four specific exercises focusing on strength training of large muscle groups, including mm. pectoralis major, rectus abdominis, quadriceps femoris, gluteus maximus and latissimus dorsi. The strength training program follows the same structure as the intervals. Clinical staff, research staff, and people with user experience will supervise the exercise sessions.
Study: NCT05971407

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischaemic Preconditioning
Description: RIPC is induced by 4 cycles of 5 minutes of healthy upper limb ischaemia followed by 5 minutes reperfusion. Ischaemia is induced by inflation of a blood pressure cuff to 20mmHg above systolic blood pressure. RIPC is conducted 3 times weekly for 6-weeks. Clinic blood pressure is measured at weeks 0, 3 and 6. 24-hour blood pressure is measured at weeks 0 and 6.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Remote Ischaemic Preconditioning
Description: Sham RIPC is induced by 4 cycles of 5 minutes of healthy upper limb ischaemia followed by 5 minutes reperfusion. Ischaemia is induced by inflation of a blood pressure cuff to 20mmHg. RIPC is conducted 3 times weekly for 6-weeks. Clinic blood pressure is measured at weeks 0, 3 and 6. 24-hour blood pressure is measured at weeks 0 and 6.
Study: NCT06332651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black beans
Description: Black beans cooked and mashed and amino acid mixture as liquid drink to make methionine the limiting amino acid in the food consumed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black beans
Description: Black beans cooked and mashed and amino acid mixture as liquid drink to make methionine the limiting amino acid in the food consumed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk
Description: Skimmed milk as liquid drink and amino acid mixture as liquid drink to make lysine the limiting amino acid in the food consumed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk
Description: Skimmed milk as liquid drink and amino acid mixture as liquid drink to make lysine the limiting amino acid in the food consumed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sorghum
Description: Sorghum cooked and mashed and amino acid mixture as liquid drink to make lysine the limiting amino acid in the food consumed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sorghum
Description: Sorghum cooked and mashed and amino acid mixture as liquid drink to make lysine the limiting amino acid in the food consumed
Study: NCT05486104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005 tablets
Description: Hemay005 tablets (15mg/tablet）will be orally administered twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005 tablets
Description: Hemay005 tablets (15mg/tablet）will be orally administered twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005 placebo tablets
Description: Hemay005 placebo tablets will be orally administered twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hemay005 placebo tablets
Description: Hemay005 placebo tablets will be orally administered twice daily.
Study: NCT06090279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OmniFlow Breathing Therapy BioFeeback System
Description: FDA approved healthcare gaming system that is used for patients who have difficulty breathing and allows the patients to participate in breathing exercises for pulmonary rehab. Each game usage itself is expected to last 15-20 minutes.
Study: NCT04737343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Patient will be treated with Leflunomide(Tuoshu, the commericial name) 30mg QD for 18 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine Tablets
Description: Patients included into this study will be treated with Azathioprine tablets 100mg QD for 18 months.
Study: NCT06326047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: NNC0519-0130 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: NNC0519-0130 will be administered subcutaneously.
Study: NCT04734444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SonoClear ACF
Description: The SonoClear ACF is intended to be used as an acoustic coupling fluid during ultrasound imaging in brain surgery of human beings
Study: NCT05201560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol Tartrate Injection
Description: Patients of this group will receive Butorphanol Tartrate Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Patients of this group will receive Fentanyl
Study: NCT06203795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Choice of the hemodialyzer
Description: Patients are dialyzed with one of the four dialyzers during the entire week, starting at Saturday (i.a. Saturday, Tuesday and Thursday). Block randomization is performed per two weeks. In week 1 and 2, patients are dialyzed with the FX CorAL 800 and the FX 800 Cordiax. In week 3 and 4 of the study, patients are dialyzed with the Solacea 19H and the Xevonta Hi20.
Study: NCT06326047

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.
Study: NCT05163808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zatolmilast
Description: Subjects will receive a 15 mg or 25 mg dose of zatolmilast (BPN14770) or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06326047

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trizepatide
Description: Trizepatide will be administered subcutaneously.
Study: NCT06506955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: futibatinib
Description: TAS-120 futibatinib monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: futibatinib, fulvestrant
Description: TAS-120 futibatinib combination therapy with fulvestrant
Study: NCT05142254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: 2.5-5 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxyurea
Description: 20 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: 20 mg/kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical placebo to tadalafil created by Bond Biochemical, who is manufacturing the tadalafil as well.
Study: NCT06202287

Intervention type: OTHER
Intervention: Balance measurements using the HUR Smart balance device, balance tests, and other surveys.
Description: 50 stroke patients will undergo balance measurements using the HUR Smart balance device and other tests.
Study: NCT05978388

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Analysis of coronary CT Angiography and CAC scoring at the time of catheter ablation
Description: Analysis of coronary CT angiography and CAC scoring and initiation of relevant derived treatment at the time of catheter ablation.
Study: NCT04397159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination Exercise
Description: Flywheel Resistance Plus Aerobic Exercise
Study: NCT06116422

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Grocery intervention - unrestricted
Description: Receives financial support in an unrestricted fashion (i.e., can use the money for whatever they need).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Grocery intervention - restricted
Description: Receives financial support restricted to the purchase of items at a grocery store, and with monthly grocery shopping coaching from a trained nutrition expert.
Study: NCT05324475

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA
Description: daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle) and nutritional counselling (SC) and 4 gram per day of BCAAs mixture. Ratio between the BCAAs will be Leucine/Isoleucine/Valine=2:1:1

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutriments
Description: daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle ) and nutritional counselling (SC) and Vitamin A 1200 mg RE, Vitamin D3 2000 IU, Thiamine B1 100 mg, Cobalamin B12 10 mcg, Ascorbic acid C 200 mg, Iron 30 mg, Selenium 100 mcg, Zinc 20 mg, Omega-3 PUFA 1 g

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: standard treatment + placebo
Description: daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle ) and nutritional counselling (SC) and maltodextrin 4 g as placebo
Study: NCT05986240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danvatirsen
Description: Danvatirsen (AZD9150) is a selective, high-affinity, antisense oligonucleotide inhibitor of signal transducer and activator of transcription 3 (or STAT3).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Danvatirsen + Venetoclax
Description: Danvatirsen (AZD9150) is a selective, high-affinity, antisense oligonucleotide inhibitor of signal transducer and activator of transcription 3 (or STAT3).~Venetoclax: Commercially available. Venetoclax is a potent, selective small molecule inhibitor of BCL-2, an anti-apoptotic protein found on some types of cancer cells.
Study: NCT04455750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib camsylate
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin Acetate
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT06247111

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Blood Pressure Monitoring + Telehealth
Description: Remote blood pressure monitoring and pharmacist led telehealth intervention for blood pressure management
Study: NCT04998552

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Cyberknife
Description: 5-10 Gy/fraction.Average of 45 minutes every other day for a total of 5 sessions (1.5-2 weeks).
Study: NCT06247111

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Participants receive usual care, no intervention.
Study: NCT04748757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human annexin A5
Description: recombinant human annexin A5, manufactured as SY-005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human annexin A5
Description: recombinant human annexin A5, manufactured as SY-005

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 50 ml
Study: NCT06504758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Retraining Program
Description: * 1st to 5th week - Breathing Retraining 10 repetitions (Pursed Lip Breathing, Diaphragmatic Breathing)~* Two days / a week The total duration of 5 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural Exerises Program (Stretching and Strengthening Exercises)
Description: * TheraBand® or Free Weight~* 1st week - neck isometrics, chin tuck, SCM - upper trapezius - pectoral major stretching, scapular retraction without weight, rowing with yellow TheraBand®, wall squat / mini squat (5 repetitions - 15 second hold for stretching exercises, 10 repetitions for strengthening exercises)~* 2nd and 3rd week - same exercises (5 repetitions - 15 second hold for stretching exercises, 15 repetitions for strengthening exercises)~* 4th and 5th week - same exercises (10 repetitions - 15 second hold for stretching exercises, 20 repetitions for strengthening exercises)~* Two days / a week,The total duration of 5 weeks
Study: NCT05529043

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MINISTOP app
Description: The MINISTOP app is a behavioural change program aiming to promote healthier diet and physical activity behaviours in pre-school children. The program consists of features such as information, monitoring and feedback (dietary variables, physical activity, and screen time) and it is built around 13 themes. The participants will have access to the app for 12-months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MINISTOP Plus Program
Description: Consists of the MINISTOP app and the Community Group Mini. The Community Group Mini consists of group activities to promote physical activity for both children and parents. The Community Group Mini will meet once per week in different playgrounds and nature reserves and will be organized by a trained group leader.
Study: NCT05484518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Method of Levels Therapy
Description: Method of Levels (MOL) is a therapy that is the direct application of Perceptual Control Theory (PCT) (Powers, 2008) which proposes that psychological distress results from a person's reduced control over important life goals. A conflict between two or more goals can occur outside of a person's awareness (Carey, Mansell \& Tai, 2014) and the achievement of one goal leaves the other incompatible goal unachievable, leading to distress (Mansell, 2012). MOL therapy aims to help people develop awareness of important goals and conflicts between them, to increase their chances of developing potential solutions. Conflict can be resolved through reorganisation; a mechanism through which random change is continuously generated until control is restored (Tai, 2016).~Therapy uses a questioning style to help clients bring their attention to their problems long enough for them to restore control. In practice clients choose the number, frequency and duration of therapy sessions
Study: NCT03959566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutezolid
Description: Sutezolid is not licensed yet. Current experience in humans up to Phase IIA. Dose according to randomization to dosing arms 2-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutezolid
Description: Sutezolid is not licensed yet. Current experience in humans up to Phase IIA. Dose according to randomization to dosing arms 2-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutezolid
Description: Sutezolid is not licensed yet. Current experience in humans up to Phase IIA. Dose according to randomization to dosing arms 2-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutezolid
Description: Sutezolid is not licensed yet. Current experience in humans up to Phase IIA. Dose according to randomization to dosing arms 2-5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bedaquiline, Delamanid, Moxifloxacin
Description: These three licensed drugs form the backbone of a new regimen to which sutezolid is added in arms 2-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline, Delamanid, Moxifloxacin
Description: These three licensed drugs form the backbone of a new regimen to which sutezolid is added in arms 2-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline, Delamanid, Moxifloxacin
Description: These three licensed drugs form the backbone of a new regimen to which sutezolid is added in arms 2-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline, Delamanid, Moxifloxacin
Description: These three licensed drugs form the backbone of a new regimen to which sutezolid is added in arms 2-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline, Delamanid, Moxifloxacin
Description: These three licensed drugs form the backbone of a new regimen to which sutezolid is added in arms 2-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam oral solution
Description: Midazolam will be administered as per probe drug use in a single dose of 2 mg at day -1 and day 14 to assess the potential of sutezolid for CYP 459 3A4 enzyme induction, as measured by its influence on the ratio of AUCs of the CYP 3A4 probe drug
Study: NCT05364931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotadutide
Description: Cotadutide administered subcutaneously once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotadutide
Description: Cotadutide administered subcutaneously once daily
Study: NCT04455750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05364931

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously once daily
Study: NCT05122273

Intervention type: DEVICE
Intervention: Stella BIO
Description: Individually planned therapeutic procedures, using, among others, the concept of EMG biofeedback
Study: NCT04671225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Groups Psychoeducation
Description: Manual-structured group psychoeducation with 8 sessions of 90 minutes over the course of 8 weeks (at one session per week). The manual is centred on behavioural principles from social education and self-regulation philosophies. All groups will have 6-8 participants and two health professionals to conduct the sessions; a psychiatric nurse and either a psychologist or a psychiatric resident. Patients will be offered to invite their relatives for 2-3 psychoeducation-days for relatives.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting-list
Description: Participants in the control group will be assigned to a waiting list and receive group-psychoeducation after the active intervention groups.
Study: NCT05199298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mandala Activity-Based Breastfeeding Program
Description: Training modules for breastfeeding and Maternal -infant attachment will be implemented with pregnant women in the study group at 32-36 weeks of gestation. The training will be explained by the researchers by shooting a video. In addition, for each week, mandala drawings will be videotaped by the researcher who received mindfulness-based art therapy training and will be sent to the Whatsapp accounts of the pregnant women. t 36 weeks of gestation, the Prenatal Attachment Scale and Spielberger State Anxiety Inventories will be sent to mothers as Google forms. The mother will be called 24 hours after the birth and the situation of having a problem with breastfeeding will be determined. In the first week, in the first and second months after the birth, questionnaire forms and online questionnaires will be applied to the mothers, apart from the follow-up and counseling in the postpartum 2nd month, the posttests of the scales
Study: NCT05113472

Intervention type: BIOLOGICAL
Intervention: Pfizer-BioNTech COVID-19 vaccine
Description: Patients who were administered any dose of the Pfizer-BioNTech COVID-19 vaccine.